Adam S Kibel

List of Publications by Year
in descending order

364	18,455	15495 65	18115 120
papers	citations	h-index	g-index

375	375	375	20427
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Quality of Life and Satisfaction with Outcome among Prostate-Cancer Survivors. New England Journal of Medicine, 2008, 358, 1250-1261.	13.9	2,030
2	Association analyses of more than 140,000 men identify 63 new prostate cancer susceptibility loci. Nature Genetics, 2018, 50, 928-936.	9.4	652
3	Tumour suppression by the human von Hippel-Lindau gene product. Nature Medicine, 1995, 1, 822-826.	15.2	636
4	Robot-assisted radical cystectomy versus open radical cystectomy in patients with bladder cancer (RAZOR): an open-label, randomised, phase 3, non-inferiority trial. Lancet, The, 2018, 391, 2525-2536.	6.3	537
5	Identification of 23 new prostate cancer susceptibility loci using the iCOGS custom genotyping array. Nature Genetics, 2013, 45, 385-391.	9.4	492
6	A meta-analysis of 87,040 individuals identifies 23 new susceptibility loci for prostate cancer. Nature Genetics, 2014, 46, 1103-1109.	9.4	408
7	Trans-ancestry genome-wide association meta-analysis of prostate cancer identifies new susceptibility loci and informs genetic risk prediction. Nature Genetics, 2021, 53, 65-75.	9.4	264
8	Prediction of Erectile Function Following Treatment for Prostate Cancer. JAMA - Journal of the American Medical Association, 2011, 306, 1205.	3.8	253
9	Analysis of Intracorporeal Compared with Extracorporeal Urinary Diversion After Robot-assisted Radical Cystectomy: Results from the International Robotic Cystectomy Consortium. European Urology, 2014, 65, 340-347.	0.9	242
10	Minimally Important Difference for the Expanded Prostate Cancer Index Composite Short Form. Urology, 2015, 85, 101-106.	0.5	241
11	Neoadjuvant Dose-Dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin With Pegfilgrastim Support in Muscle-Invasive Urothelial Cancer: Pathologic, Radiologic, and Biomarker Correlates. Journal of Clinical Oncology, 2014, 32, 1889-1894.	0.8	229
12	Prospective Study of [¹⁸F]Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography for Staging of Muscle-Invasive Bladder Carcinoma. Journal of Clinical Oncology, 2009, 27, 4314-4320.	0.8	219
13	The association between germline <scp>BRCA2</scp> variants and sensitivity to platinumâ€based chemotherapy among men with metastatic prostate cancer. Cancer, 2017, 123, 3532-3539.	2.0	217
14	Contemporary Role of Systematic Prostate Biopsies: Indications, Techniques, and Implications for Patient Care. European Urology, 2013, 63, 214-230.	0.9	214
15	The Learning Curve of Robot-Assisted Radical Cystectomy: Results from the International Robotic Cystectomy Consortium. European Urology, 2010, 58, 197-202.	0.9	213
16	11C-acetate PET imaging of prostate cancer: detection of recurrent disease at PSA relapse. Journal of Nuclear Medicine, 2003, 44, 549-55.	2.8	209
17	Propensity-Matched Comparison of Morbidity and Costs of Open and Robot-Assisted Radical Cystectomies: A Contemporary Population-Based Analysis in the United States. European Urology, 2014, 66, 569-576.	0.9	205
18	Genome-wide association study of prostate cancer in men of African ancestry identifies a susceptibility locus at 17q21. Nature Genetics, 2011, 43, 570-573.	9.4	198

#	Article	IF	Citations
19	Nomogram Predicting Prostate Cancerâ€“specific Mortality for Men with Biochemical Recurrence After Radical Prostatectomy. European Urology, 2015, 67, 1160-1167.	0.9	192
20	Defining a Standard Set of Patient-centered Outcomes for Men with Localized Prostate Cancer. European Urology, 2015, 67, 460-467.	0.9	190
21	Epidemiology and Prevention of Prostate Cancer. European Urology Oncology, 2021, 4, 877-892.	2.6	190
22	Complications After Robot-assisted Radical Cystectomy: Results from the International Robotic Cystectomy Consortium. European Urology, 2013, 64, 52-57.	0.9	189
23	PALB2,CHEK2andATMrare variants and cancer risk: data from COGS. Journal of Medical Genetics, 2016, 53, 800-811.	1.5	174
24	SnoRNA U50 is a candidate tumor-suppressor gene at 6q14.3 with a mutation associated with clinically significant prostate cancer. Human Molecular Genetics, 2007, 17, 1031-1042.	1.4	170
25	Comparative Effectiveness of Robot-Assisted and Open Radical Prostatectomy in the Postdissemination Era. Journal of Clinical Oncology, 2014, 32, 1419-1426.	0.8	169
26	Genome-Wide Meta-Analyses of Breast, Ovarian, and Prostate Cancer Association Studies Identify Multiple New Susceptibility Loci Shared by at Least Two Cancer Types. Cancer Discovery, 2016, 6, 1052-1067.	7.7	157
27	PROGNOSTIC FEATURES OF TERATOMAS WITH MALIGNANT TRANSFORMATION: A CLINICOPATHOLOGICAL STUDY OF 21 CASES. Journal of Urology, 1998, 159, 859-863.	0.2	153
28	Polygenic hazard score to guide screening for aggressive prostate cancer: development and validation in large scale cohorts. BMJ: British Medical Journal, 2018, 360, j5757.	2.4	153
29	Comparative Analysis of Outcomes and Costs Following Open Radical Cystectomy Versus Robot-Assisted Laparoscopic Radical Cystectomy: Results From the US Nationwide Inpatient Sample. European Urology, 2012, 61, 1239-1244.	0.9	149
30	Vitamin D-related genes, serum vitamin D concentrations and prostate cancer risk. Carcinogenesis, 2009, 30, 769-776.	1.3	142
31	Association Between Combined TMPRSS2:ERG and PCA3 RNA Urinary Testing and Detection of Aggressive Prostate Cancer. JAMA Oncology, 2017, 3, 1085.	3.4	120
32	EZH2 inhibition activates a dsRNAâ€“STINGâ€“interferon stress axis that potentiates response to PD-1 checkpoint blockade in prostate cancer. Nature Cancer, 2021, 2, 444-456.	5.7	118
33	Comparative Effectiveness of Trimodal Therapy Versus Radical Cystectomy for Localized Muscle-invasive Urothelial Carcinoma of the Bladder. European Urology, 2017, 72, 483-487.	0.9	110
34	Effect of Minimally Invasive Surgery on the Risk for Surgical Site Infections. JAMA Surgery, 2014, 149, 1039.	2.2	109
35	Effectiveness of Adjuvant Chemotherapy After Radical Nephroureterectomy for Locally Advanced and/or Positive Regional Lymph Node Upper Tract Urothelial Carcinoma. Journal of Clinical Oncology, 2017, 35, 852-860.	0.8	104
36	Racial/Ethnic Disparities in Perioperative Outcomes of Major Procedures. Annals of Surgery, 2015, 262, 955-964.	2.1	101

#	Article	IF	Citations
37	Fine-mapping identifies multiple prostate cancer risk loci at 5p15, one of which associates with TERT expression. Human Molecular Genetics, 2013, 22, 2520-2528.	1.4	100
38	Lymphadenectomy at the time of robotâ€assisted radical cystectomy: results from the International Robotic Cystectomy Consortium. BJU International, 2011, 107, 642-646.	1.3	93
39	NCCN Guidelines Insights: Bladder Cancer, Version 2.2016. Journal of the National Comprehensive Cancer Network: JNCCN, 2016, 14, 1213-1224.	2.3	93
40	Laparoscopic renal surgery and the risk of rhabdomyolysis: Diagnosis and treatment. Urology, 2005, 66, 29-35.	0.5	88
41	Validation of Genome-Wide Prostate Cancer Associations in Men of African Descent. Cancer Epidemiology Biomarkers and Prevention, 2011, 20, 23-32.	1.1	88
42	Fine-mapping of prostate cancer susceptibility loci in a large meta-analysis identifies candidate causal variants. Nature Communications, 2018, 9, 2256.	5.8	88
43	Shared heritability and functional enrichment across six solid cancers. Nature Communications, 2019, 10, 431.	5.8	88
44	Assessment of Time-to-Treatment Initiation and Survival in a Cohort of Patients With Common Cancers. JAMA Network Open, 2020, 3, e2030072.	2.8	87
45	Racial Differences in the Surgical Care of Medicare Beneficiaries With Localized Prostate Cancer. JAMA Oncology, 2016, 2, 85.	3.4	86
46	Variation in KLK genes, prostate-specific antigen and risk of prostate cancer. Nature Genetics, 2008, 40, 1032-1034.	9.4	83
47	11C-Acetate PET/CT Before Radical Prostatectomy: Nodal Staging and Treatment Failure Prediction. Journal of Nuclear Medicine, 2013, 54, 699-706.	2.8	81
48	Neoadjuvant Enzalutamide Prior to Prostatectomy. Clinical Cancer Research, 2017, 23, 2169-2176.	3.2	80
49	Impact of surgeon volume on the morbidity and costs of radical cystectomy in the <scp>USA</scp>: a contemporary populationâ€based analysis. BJU International, 2015, 115, 713-721.	1.3	79
50	The impact of robotic surgery on the surgical management of prostate cancer in the <scp>USA</scp>. BJU International, 2015, 115, 929-936.	1.3	78
51	Evaluation of Intense Androgen Deprivation Before Prostatectomy: A Randomized Phase II Trial of Enzalutamide and Leuprolide With or Without Abiraterone. Journal of Clinical Oncology, 2019, 37, 923-931.	0.8	78
52	The effects of height and BMI on prostate cancer incidence and mortality: a Mendelian randomization study in 20,848 cases and 20,214 controls from the PRACTICAL consortium. Cancer Causes and Control, 2015, 26, 1603-1616.	0.8	77
53	CDKN1A and CDKN1B polymorphisms and risk of advanced prostate carcinoma. Cancer Research, 2003, 63, 2033-6.	0.4	76
54	Prostate Cancer (PCa) Risk Variants and Risk of Fatal PCa in the National Cancer Institute Breast and Prostate Cancer Cohort Consortium. European Urology, 2014, 65, 1069-1075.	0.9	75

#	Article	IF	Citations
55	Transperineal In-Bore 3-T MR Imagingâ€“guided Prostate Biopsy: A Prospective Clinical Observational Study. Radiology, 2015, 274, 170-180.	3.6	75
56	Predictors of Recurrence, and Progression-Free and Overall Survival following Open versus Robotic Radical Cystectomy: Analysis from the RAZOR Trial with a 3-Year Followup. Journal of Urology, 2020, 203, 522-529.	0.2	75
57	Baseline Prostate-Specific Antigen Levels in Midlife Predict Lethal Prostate Cancer. Journal of Clinical Oncology, 2016, 34, 2705-2711.	0.8	74
58	The Gleason Score of Tumor at the Margin in Radical Prostatectomy is Predictive of Biochemical Recurrence. American Journal of Surgical Pathology, 2010, 34, 994-1001.	2.1	73
59	The <scp>RAZOR</scp> (randomized open vs robotic cystectomy) trial: study design and trial update. BJU International, 2015, 115, 198-205.	1.3	73
60	Mortality After Prostate Cancer Treatment with Radical Prostatectomy, External-Beam Radiation Therapy, or Brachytherapy in Men Without Comorbidity. European Urology, 2013, 64, 372-378.	0.9	71
61	Clinicalâ€“Pathologic Stage Discrepancy in Bladder Cancer Patients Treated With Radical Cystectomy: Results From the National Cancer Data Base. International Journal of Radiation Oncology Biology Physics, 2014, 88, 1048-1056.	0.4	71
62	Efficacy of High-Intensity Local Treatment for Metastatic Urothelial Carcinoma of the Bladder: A Propensity Scoreâ€“Weighted Analysis From the National Cancer Data Base. Journal of Clinical Oncology, 2016, 34, 3529-3536.	0.8	70
63	Cognitive Impairment in Men with Prostate Cancer Treated with Androgen Deprivation Therapy: A Systematic Review and Meta-Analysis. Journal of Urology, 2018, 199, 1417-1425.	0.2	70
64	Impact of smoking on perioperative outcomes after major surgery. American Journal of Surgery, 2015, 210, 221-229.e6.	0.9	69
65	The Effect of Body Mass Index on Perioperative Outcomes After Major Surgery: Results from the National Surgical Quality Improvement Program (ACSâ€NSQIP) 2005â€“2011. World Journal of Surgery, 2015, 39, 2376-2385.	0.8	69
66	Selective targeting of PARP-2 inhibits androgen receptor signaling and prostate cancer growth through disruption of FOXA1 function. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 14573-14582.	3.3	69
67	Blood lipids and prostate cancer: a Mendelian randomization analysis. Cancer Medicine, 2016, 5, 1125-1136.	1.3	68
68	Multiple novel prostate cancer susceptibility signals identified by fine-mapping of known risk loci among Europeans. Human Molecular Genetics, 2015, 24, 5589-5602.	1.4	67
69	Positive Margin During Partial Nephrectomy: Does Cancer Remain in the Renal Remnant?. Urology, 2011, 77, 1400-1403.	0.5	66
70	Decipher test impacts decision making among patients considering adjuvant and salvage treatment after radical prostatectomy: Interim results from the Multicenter Prospective PROâ€IMPACT study. Cancer, 2017, 123, 2850-2859.	2.0	66
71	Morbidity and Mortality After Benign Prostatic Hyperplasia Surgery: Data from the American College of Surgeons National Surgical Quality Improvement Program. Journal of Endourology, 2014, 28, 831-840.	1.1	64
72	Effectiveness of adjuvant chemotherapy after radical nephroureterectomy for locally advanced and/or positive regional lymph node upper tract urothelial carcinoma.. Journal of Clinical Oncology, 2017, 35, 305-305.	0.8	63

#	Article	IF	Citations
73	Surgical treatment of renal neoplasia: evolving toward a laparoscopic standard of care. Urology, 2003, 62, 821-826.	0.5	62
74	Cytoreductive nephrectomy in patients with metastatic nonâ€clearâ€cell renal cell carcinoma (<scp>RCC</scp>). BJU International, 2014, 113, E67-74.	1.3	62
75	Generalizability of established prostate cancer risk variants in men of <scp>A</scp>frican ancestry. International Journal of Cancer, 2015, 136, 1210-1217.	2.3	62
76	Variations in the Costs of Radical Cystectomy for Bladder Cancer in the USA. European Urology, 2018, 73, 374-382.	0.9	62
77	Association of Care at Minority-Serving vs Nonâ€“Minority-Serving Hospitals With Use of Palliative Care Among Racial/Ethnic Minorities With Metastatic Cancer in the United States. JAMA Network Open, 2019, 2, e187633.	2.8	60
78	Familial Calcium Stone Disease:TaqI Polymorphism and the Vitamin D Receptor. Journal of Endourology, 1999, 13, 313-316.	1.1	59
79	Mental health outcomes in elderly men with prostate cancer1Equal contribution.. Urologic Oncology: Seminars and Original Investigations, 2014, 32, 1333-1340.	0.8	59
80	Sequencing of Sipuleucel-T and Androgen Deprivation Therapy in Men with Hormone-Sensitive Biochemically Recurrent Prostate Cancer: A Phase II Randomized Trial. Clinical Cancer Research, 2017, 23, 2451-2459.	3.2	58
81	Adjuvant Chemotherapy vs Observation for Patients With Adverse Pathologic Features at Radical Cystectomy Previously Treated With Neoadjuvant Chemotherapy. JAMA Oncology, 2018, 4, 225.	3.4	58
82	Prostate Cancer Risk Associated Loci in African Americans. Cancer Epidemiology Biomarkers and Prevention, 2009, 18, 2145-2149.	1.1	57
83	Two Novel Susceptibility Loci for Prostate Cancer in Men of African Ancestry. Journal of the National Cancer Institute, 2017, 109, .	3.0	57
84	Constitutive Î²-Catenin Activation Induces Male-Specific Tumorigenesis in the Bladder Urothelium. Cancer Research, 2013, 73, 5914-5925.	0.4	56
85	A Large-Scale Analysis of Genetic Variants within Putative miRNA Binding Sites in Prostate Cancer. Cancer Discovery, 2015, 5, 368-379.	7.7	56
86	Impact of adjuvant chemotherapy in patients with adverse features and variant histology at radical cystectomy for muscleâ€invasive carcinoma of the bladder: Does histologic subtype matter?. Cancer, 2019, 125, 1449-1458.	2.0	56
87	Hemostatic laparoscopic partial nephrectomy assisted by a water-cooled, high-density, monopolar device without renal vascular control. Urology, 2003, 61, 906-909.	0.5	54
88	Prostate-Specific Antigen Density Predicts Adverse Pathology and Increased Risk of Biochemical Failure. Urology, 2007, 69, 1121-1127.	0.5	54
89	Prediction of individual genetic risk to prostate cancer using a polygenic score. Prostate, 2015, 75, 1467-1474.	1.2	54
90	Evaluation of the contribution of demographics, access to health care, treatment, and tumor characteristics to racial differences in survival of advanced prostate cancer. Prostate Cancer and Prostatic Diseases, 2019, 22, 125-136.	2.0	53

#	Article	IF	Citations
91	Comparative effectiveness of robot-assisted vs. open radical cystectomy. Urologic Oncology: Seminars and Original Investigations, 2018, 36, 88.e1-88.e9.	0.8	52
92	Adjuvant leuprolide with or without docetaxel in patients with highâ€risk prostate cancer after radical prostatectomy (TAXâ€3501). Cancer, 2013, 119, 3610-3618.	2.0	51
93	Short-term perioperative outcomes of patients treated with radical cystectomy for bladder cancer included in the National Surgical Quality Improvement Program (NSQIP) database. Canadian Urological Association Journal, 2014, 8, 681.	0.3	51
94	Does Previous Robot-assisted Radical Prostatectomy Experience Affect Outcomes at Robot-assisted Radical Cystectomy? Results from the International Robotic Cystectomy Consortium. Urology, 2010, 76, 1111-1116.	0.5	50
95	Predictors of 30-day acute kidney injury following radical and partial nephrectomy for renal cell carcinoma. Urologic Oncology: Seminars and Original Investigations, 2014, 32, 1259-1266.	0.8	50
96	Atlas of prostate cancer heritability in European and African-American men pinpoints tissue-specific regulation. Nature Communications, 2016, 7, 10979.	5.8	50
97	Evaluation of a novel precision templateâ€guided biopsy system for detecting prostate cancer. BJU International, 2008, 102, 546-550.	1.3	49
98	Impact of surgeon and volume on extended lymphadenectomy at the time of robotâ€assisted radical cystectomy: results from the International Robotic Cystectomy Consortium (<scp>IRCC</scp>). BJU International, 2013, 111, 1075-1080.	1.3	49
99	Prognostic Impact of Comorbidity in Patients with Bladder Cancer. European Urology, 2008, 53, 581-589.	0.9	48
100	The 2011â€“2016 Transdisciplinary Research on Energetics and Cancer (TREC) Initiative: Rationale and Design. Cancer Causes and Control, 2013, 24, 695-704.	0.8	48
101	Post prostatectomy outcomes of patients with high-risk prostate cancer treated with neoadjuvant androgen blockade. Prostate Cancer and Prostatic Diseases, 2018, 21, 364-372.	2.0	48
102	Ability of Linear Length of Positive Margin in Radical Prostatectomy Specimens to Predict Biochemical Recurrence. Urology, 2011, 77, 1409-1414.	0.5	46
103	Early oncologic outcomes of robotic vs. open radical cystectomy for urothelial cancer. Urologic Oncology: Seminars and Original Investigations, 2013, 31, 894-898.	0.8	46
104	The impact of resident involvement in minimally-invasive urologic oncology procedures. Canadian Urological Association Journal, 2014, 8, 334.	0.3	46
105	Racial and Ethnic Variation in PSA Testing and Prostate Cancer Incidence Following the 2012 USPSTF Recommendation. Journal of the National Cancer Institute, 2021, 113, 719-726.	3.0	45
106	Association of hereditary prostate cancer gene polymorphic variants with sporadic aggressive prostate carcinoma. Prostate, 2006, 66, 49-56.	1.2	44
107	Prostate Cancer Predisposition Loci and Risk of Metastatic Disease and Prostate Cancer Recurrence. Clinical Cancer Research, 2011, 17, 1075-1081.	3.2	44
108	Impact of Comorbidity on Overall Survival in Patients Surgically Treated for Renal Cell Carcinoma. Urology, 2008, 72, 359-363.	0.5	43

#	Article	IF	Citations
109	Patterns of Declining Use and the Adverse Effect of Primary Androgen Deprivation on All-cause Mortality in Elderly Men with Prostate Cancer. European Urology, 2015, 68, 32-39.	0.9	43
110	Trends of acute kidney injury after radical or partial nephrectomy for renal cell carcinoma. Urologic Oncology: Seminars and Original Investigations, 2016, 34, 293.e1-293.e10.	0.8	43
111	Racial Disparity in Delivering Definitive Therapy for Intermediate/High-risk Localized Prostate Cancer: The Impact of Facility Features and Socioeconomic Characteristics. European Urology, 2018, 73, 445-451.	0.9	43
112	Germline variation at 8q24 and prostate cancer risk in men of European ancestry. Nature Communications, 2018, 9, 4616.	5.8	43
113	Baseline Prostate-specific Antigen Level in Midlife and Aggressive Prostate Cancer in Black Men. European Urology, 2019, 75, 399-407.	0.9	43
114	Comparative Effectiveness of Radical Prostatectomy Versus External Beam Radiation Therapy Plus Brachytherapy in Patients with High-risk Localized Prostate Cancer. European Urology, 2019, 75, 552-555.	0.9	43
115	Pubertal development and prostate cancer risk: Mendelian randomization study in a population-based cohort. BMC Medicine, 2016, 14, 66.	2.3	42
116	Surgeon and Hospital Level Variation in the Costs of Robot-Assisted Radical Prostatectomy. Journal of Urology, 2016, 196, 1090-1095.	0.2	42
117	The association of hypoalbuminemia with early perioperative outcomes â€“ A comprehensive assessment across 16 major procedures. American Journal of Surgery, 2017, 214, 871-883.	0.9	42
118	Variation in the use of active surveillance for lowâ€risk prostate cancer. Cancer, 2018, 124, 55-64.	2.0	40
119	Evaluating the cost of surveillance for non-muscle-invasive bladder cancer: an analysis based on risk categories. World Journal of Urology, 2019, 37, 2059-2065.	1.2	40
120	Polygenic hazard score is associated with prostate cancer in multi-ethnic populations. Nature Communications, 2021, 12, 1236.	5.8	40
121	Suicide and accidental deaths among patients with nonâ€metastatic prostate cancer. BJU International, 2016, 118, 286-297.	1.3	39
122	Functional roles and potential clinical application of miRNAâ€345â€5p in prostate cancer. Prostate, 2018, 78, 927-937.	1.2	39
123	Contemporary national trends in prostate cancer risk profile at diagnosis. Prostate Cancer and Prostatic Diseases, 2020, 23, 81-87.	2.0	39
124	Evaluation of a Multiethnic Polygenic Risk Score Model for Prostate Cancer. Journal of the National Cancer Institute, 2022, 114, 771-774.	3.0	39
125	Are Biochemical Recurrence Outcomes Similar After Radical Prostatectomy and Radiation Therapy? Analysis of Prostate Cancerâ€“Specific Mortality by Nomogram-predicted Risks of Biochemical Recurrence. European Urology, 2015, 67, 204-209.	0.9	38
126	Human vascular progenitor cells derived from renal arteries are endothelial-like and assist in the repair of injured renal capillary networks. Kidney International, 2017, 91, 129-143.	2.6	38

#	Article	IF	Citations
127	Racial Disparities in End-of-Life Care Among Patients With Prostate Cancer: A Population-Based Study. Journal of the National Comprehensive Cancer Network: JNCCN, 2015, 13, 1131-1138.	2.3	37
128	Geographic Distribution of Racial Differences in Prostate Cancer Mortality. JAMA Network Open, 2020, 3, e201839.	2.8	37
129	Ureteral injury in laparoscopic gynecologic surgery. Reviews in Obstetrics and Gynecology, 2012, 5, 106-11.	0.7	37
130	The Effect of Resident Involvement on Perioperative Outcomes in Transurethral Urologic Surgeries. Journal of Surgical Education, 2015, 72, 1018-1025.	1.2	36
131	Causes of hospital readmissions after urologic cancer surgery. Urologic Oncology: Seminars and Original Investigations, 2016, 34, 236.e1-236.e11.	0.8	36
132	Effect of a Behavioral Intervention to Increase Vegetable Consumption on Cancer Progression Among Men With Early-Stage Prostate Cancer. JAMA - Journal of the American Medical Association, 2020, 323, 140.	3.8	36
133	Methylation and mutational analysis of p27kip1 in prostate carcinoma. Prostate, 2001, 48, 248-253.	1.2	35
134	Who should be included in a clinical trial of screening for bladder cancer?. Cancer, 2013, 119, 143-149.	2.0	35
135	Prophylactic Antibiotics and Postoperative Complications of Radical Cystectomy: A Population Based Analysis in the United States. Journal of Urology, 2017, 198, 297-304.	0.2	35
136	The role of lymphovascular space invasion in renal cell carcinoma as a prognostic marker of survival after curative resection. Urologic Oncology: Seminars and Original Investigations, 2011, 29, 738-744.	0.8	34
137	Fine-Mapping the HOXB Region Detects Common Variants Tagging a Rare Coding Allele: Evidence for Synthetic Association in Prostate Cancer. PLoS Genetics, 2014, 10, e1004129.	1.5	34
138	Contemporary Nationwide Patterns of Self-reported Prostate-Specific Antigen Screening. JAMA Internal Medicine, 2014, 174, 1839.	2.6	33
139	Determinants of cancer screening in Asian-Americans. Cancer Causes and Control, 2016, 27, 989-998.	0.8	33
140	Androgen Deprivation Therapy Is Associated With Prolongation of QTc Interval in Men With Prostate Cancer. Journal of the Endocrine Society, 2018, 2, 485-496.	0.1	33
141	A Germline Variant at 8q24 Contributes to Familial Clustering of Prostate Cancer in Men of African Ancestry. European Urology, 2020, 78, 316-320.	0.9	32
142	Morbidity and Mortality of Locally Advanced Prostate Cancer: A Population Based Analysis Comparing Radical Prostatectomy versus External Beam Radiation. Journal of Urology, 2017, 198, 1061-1068.	0.2	31
143	Liver Disease in Men Undergoing Androgen Deprivation Therapy for Prostate Cancer. Journal of Urology, 2018, 200, 573-581.	0.2	31
144	Sex-specific Differences in the Quality of Treatment of Muscle-invasive Bladder Cancer Do Not Explain the Overall Survival Discrepancy. European Urology Focus, 2021, 7, 124-131.	1.6	31

#	Article	IF	Citations
145	Quality of Care in the Treatment of Localized Intermediate and High Risk Prostate Cancer at Minority Serving Hospitals. Journal of Urology, 2019, 201, 735-741.	0.2	31
146	Modified renal morcellation for renal cell carcinoma: laboratory experience and early clinical application. Urology, 2003, 62, 632-634.	0.5	30
147	Associations of specific postoperative complications with costs after radical cystectomy. BJU International, 2018, 121, 428-436.	1.3	30
148	Androgen receptorâ€regulated miRNAâ€193aâ€3p targets AJUBA to promote prostate cancer cell migration. Prostate, 2017, 77, 1000-1011.	1.2	29
149	The role of systemic cytotoxic therapy for prostate cancer. BJU International, 2009, 103, 8-17.	1.3	28
150	Alcohol consumption and prostate cancer incidence and progression: A Mendelian randomisation study. International Journal of Cancer, 2017, 140, 75-85.	2.3	28
151	Androgen receptor-mediated downregulation of microRNA-221 and -222 in castration-resistant prostate cancer. PLoS ONE, 2017, 12, e0184166.	1.1	28
152	Patterns of multiple recurrences of superficial (Ta/T1) transitional cell carcinoma of bladder and effects of clinicopathologic and biochemical factors. Cancer, 2002, 95, 1239-1246.	2.0	27
153	Genome-Wide Association Study of Prostate Cancerâ€“Specific Survival. Cancer Epidemiology Biomarkers and Prevention, 2015, 24, 1796-1800.	1.1	27
154	Antigen-Specific CD8 Lytic Phenotype Induced by Sipuleucel-T in Hormone-Sensitive or Castration-Resistant Prostate Cancer and Association with Overall Survival. Clinical Cancer Research, 2018, 24, 4662-4671.	3.2	27
155	Targeting the MIF/CXCR7/AKT Signaling Pathway in Castration-Resistant Prostate Cancer. Molecular Cancer Research, 2019, 17, 263-276.	1.5	27
156	A Genetic Risk Score to Personalize Prostate Cancer Screening, Applied to Population Data. Cancer Epidemiology Biomarkers and Prevention, 2020, 29, 1731-1738.	1.1	27
157	Assessing the role of insulinâ€like growth factors and binding proteins in prostate cancer using Mendelian randomization: Genetic variants as instruments for circulating levels. International Journal of Cancer, 2016, 139, 1520-1533.	2.3	26
158	Effects of Androgen Deprivation Therapy on Pain Perception, Quality of Life, and Depression in Men With Prostate Cancer. Journal of Pain and Symptom Management, 2018, 55, 307-317.e1.	0.6	26
159	Access denied: The relationship between patient insurance status and access to highâ€volume hospitals. Cancer, 2021, 127, 577-585.	2.0	26
160	Treatment Decision Making in Patients with Bladder Cancer. Bladder Cancer, 2015, 1, 151-158.	0.2	25
161	The burden of skeletal-related events in patients with prostate cancer and bone metastasis. Urologic Oncology: Seminars and Original Investigations, 2015, 33, 17.e9-17.e18.	0.8	24
162	Mechanisms responsible for reduced erythropoiesis during androgen deprivation therapy in men with prostate cancer. American Journal of Physiology - Endocrinology and Metabolism, 2018, 315, E1185-E1193.	1.8	24

#	Article	IF	Citations
163	Levels and patterns of selfâ€reported and objectivelyâ€measured freeâ€living physical activity among prostate cancer survivors: A prospective cohort study. Cancer, 2019, 125, 798-806.	2.0	24
164	Africanâ€specific improvement of a polygenic hazard score for age at diagnosis of prostate cancer. International Journal of Cancer, 2021, 148, 99-105.	2.3	24
165	Readmissions after major urologic cancer surgery. Canadian Journal of Urology, 2014, 21, 7537-46.	0.0	24
166	Association between polymorphisms in cell cycle genes and advanced prostate carcinoma. Prostate, 2008, 68, 1179-1186.	1.2	23
167	A Comparison of 30-Day Perioperative Outcomes in Open Versus Minimally Invasive Nephroureterectomy for Upper Tract Urothelial Carcinoma: Analysis of 896 Patients from the American College of Surgeons-National Surgical Quality Improvement Program Database. Journal of Endourology, 2015, 29, 1052-1058.	1.1	23
168	Polyunsaturated fatty acids and prostate cancer risk: a Mendelian randomisation analysis from the PRACTICAL consortium. British Journal of Cancer, 2016, 115, 624-631.	2.9	23
169	Comparison of Hospital Readmission After Total Hip and Total Knee Arthroplasty vs Spinal Surgery After Implementation of the Hospital Readmissions Reduction Program. JAMA Network Open, 2019, 2, e194634.	2.8	23
170	Doseâ€dependent effect of androgen deprivation therapy for localized prostate cancer on adverse cardiac events. BJU International, 2016, 118, 221-229.	1.3	22
171	Rare Variation in TET2 Is Associated with Clinically Relevant Prostate Carcinoma in African Americans. Cancer Epidemiology Biomarkers and Prevention, 2016, 25, 1456-1463.	1.1	22
172	Metabolomics of Prostate Cancer Gleason Score in Tumor Tissue and Serum. Molecular Cancer Research, 2021, 19, 475-484.	1.5	22
173	Insulinemic and Inflammatory Dietary Patterns and Risk of Prostate Cancer. European Urology, 2021, 79, 405-412.	0.9	22
174	A Rare Germline HOXB13 Variant Contributes to Risk of Prostate Cancer in Men of African Ancestry. European Urology, 2022, 81, 458-462.	0.9	22
175	Expression mapping at 12p12-13 in advanced prostate carcinoma. International Journal of Cancer, 2004, 109, 668-672.	2.3	21
176	Burden of Hospital Admissions and Utilization of Hospice Care in Metastatic Prostate Cancer Patients. Urology, 2015, 85, 343-350.	0.5	21
177	The Impact of Resident Involvement in Male One-stage Anterior Urethroplasties. Urology, 2015, 85, 937-941.	0.5	21
178	Temporal trends in receipt of adequate lymphadenectomy in bladder cancer 1988 to 2010. Urologic Oncology: Seminars and Original Investigations, 2015, 33, 504.e9-504.e17.	0.8	21
179	The effect of treatment at minority-serving hospitals on outcomes for bladder cancer. Urologic Oncology: Seminars and Original Investigations, 2018, 36, 238.e7-238.e17.	0.8	21
180	The association of marital status and mortality among men with early-stage prostate cancer treated with radical prostatectomy: insight into post-prostatectomy survival strategies. Cancer Causes and Control, 2019, 30, 871-876.	0.8	21

#	Article	IF	Citations
181	Circulating Metabolic Biomarkers of Screen-Detected Prostate Cancer in the ProtecT Study. Cancer Epidemiology Biomarkers and Prevention, 2019, 28, 208-216.	1.1	21
182	Comparing the Association Between Insurance and Mortality in Ovarian, Pancreatic, Lung, Colorectal, Prostate, and Breast Cancers. Journal of the National Comprehensive Cancer Network: JNCCN, 2019, 17, 1049-1058.	2.3	21
183	Reassessing the value of highâ€volume cancer care in the era of precision medicine. Cancer, 2018, 124, 1319-1321.	2.0	20
184	Neoadjuvant Androgen Deprivation Therapy Prior to Radical Prostatectomy: Recent Trends in Utilization and Association with Postoperative Surgical Margin Status. Annals of Surgical Oncology, 2019, 26, 297-305.	0.7	20
185	Impact of tumor, treatment, and access on outcomes in bladder cancer: Can equal access overcome raceâ€based differences in survival?. Cancer, 2019, 125, 1319-1329.	2.0	20
186	Risk of Dementia and Depression in Young and Middle-aged Men Presenting with Nonmetastatic Prostate Cancer Treated with Androgen Deprivation Therapy. European Urology Oncology, 2021, 4, 66-72.	2.6	20
187	A guide for clinicians in the evaluation of emerging molecular diagnostics for newly diagnosed prostate cancer. Reviews in Urology, 2014, 16, 172-80.	0.9	20
188	Mutational analysis of ETV6 in prostate carcinoma. Prostate, 2002, 52, 305-310.	1.2	19
189	The Health Care Burden of Skeletal Related Events in Patients with Renal Cell Carcinoma and Bone Metastasis. Journal of Urology, 2014, 191, 1678-1684.	0.2	19
190	Heterogeneity in Definitions of High-risk Prostate Cancer and Varying Impact on Mortality Rates after Radical Prostatectomy. European Urology Oncology, 2018, 1, 143-148.	2.6	19
191	Adoption of immunotherapy in the community for patients diagnosed with metastatic melanoma. , 2019, 7, 289.		19
192	The impact of underinsurance on bladder cancer diagnosis, survival, and care delivery for individuals under the age of 65Âyears. Cancer, 2020, 126, 496-505.	2.0	19
193	Clinical Utility of a Genomic Classifier in Men Undergoing Radical Prostatectomy: The PRO-IMPACT Trial. Practical Radiation Oncology, 2020, 10, e82-e90.	1.1	19
194	Association of CASP8 D302H polymorphism with reduced risk of aggressive prostate carcinoma. Prostate, 2010, 70, 646-653.	1.2	18
195	Laparoscopic Retroperitoneal Lymph Node Dissection for Low-Stage Cancer: A Washington University Update. Journal of Endourology, 2011, 25, 1753-1757.	1.1	18
196	Urolithiasis and Urinary Tract Infection Among Patients With Inflammatory Bowel Disease: A Review of US Emergency Department Visits between 2006 and 2009. Urology, 2015, 85, 764-770.	0.5	18
197	Meat, Fish, Poultry, and Egg Intake at Diagnosis and Risk of Prostate Cancer Progression. Cancer Prevention Research, 2016, 9, 933-941.	0.7	18
198	Assessment of Out-of-Pocket Costs for Robotic Cancer Surgery in US Adults. JAMA Network Open, 2020, 3, e1919185.	2.8	18

#	Article	IF	Citations
199	Intravesical Bacille Calmette-GuÃ©rin Therapy for Non-Muscle-Invasive Bladder Cancer: Effects of Concurrent Statin Therapy. Journal of the American College of Surgeons, 2009, 209, 248-253.	0.2	17
200	Gene and pathway level analyses of germline DNA-repair gene variants and prostate cancer susceptibility using the iCOGS-genotyping array. British Journal of Cancer, 2016, 114, 945-952.	2.9	17
201	Investigating the possible causal role of coffee consumption with prostate cancer risk and progression using Mendelian randomization analysis. International Journal of Cancer, 2017, 140, 322-328.	2.3	17
202	Current Staging Strategies for Muscle-Invasive Bladder Cancer and Upper Tract Urothelial Cell Carcinoma. Urologic Clinics of North America, 2018, 45, 143-154.	0.8	17
203	Effect of Nonurothelial Histologic Variants on the Outcomes of Radical Cystectomy for Nonmetastatic Muscle-invasive Urinary Bladder Cancer. Clinical Genitourinary Cancer, 2018, 16, e129-e139.	0.9	17
204	Examining the relationship between complications and perioperative mortality following radical cystectomy: a populationâ€based analysis. BJU International, 2019, 124, 40-46.	1.3	17
205	Risk of dementia following androgen deprivation therapy for treatment of prostate cancer. Prostate Cancer and Prostatic Diseases, 2020, 23, 410-418.	2.0	17
206	Effect of Preoperative Angina Pectoris on Cardiac Outcomes in Patients With Previous Myocardial Infarction Undergoing Major Noncardiac Surgery (Data from ACS-NSQIP). American Journal of Cardiology, 2015, 115, 1080-1084.	0.7	16
207	Comparison of 30-day perioperative outcomes in adults undergoing open versus minimally invasive pyeloplasty for ureteropelvic junction obstruction: analysis of 593 patients in a prospective national database. World Journal of Urology, 2015, 33, 2107-2113.	1.2	16
208	Impact of adequate pelvic lymph node dissection on overall survival after radical cystectomy: A stratified analysis by clinical stage and receipt of neoadjuvant chemotherapy. Urologic Oncology: Seminars and Original Investigations, 2018, 36, 78.e13-78.e19.	0.8	16
209	The CHEK2 Variant C.349A>G Is Associated with Prostate Cancer Risk and Carriers Share a Common Ancestor. Cancers, 2020, 12, 3254.	1.7	16
210	Additional SNPs improve risk stratification of a polygenic hazard score for prostate cancer. Prostate Cancer and Prostatic Diseases, 2021, 24, 532-541.	2.0	16
211	Renaming Gleason Score 6 Prostate to Noncancer: A Flawed Idea Scientifically and for Patient Care. Journal of Clinical Oncology, 2022, 40, 3106-3109.	0.8	16
212	G1/S cell cycle proteins as markers of aggressive prostate carcinoma. Urology, 2000, 55, 316-322.	0.5	15
213	Laparoscopic Partial Nephrectomy with a Novel Electrosurgical Snare in a Porcine Model. Journal of Endourology, 2002, 16, 673-679.	1.1	15
214	High-risk localized prostate cancer: role of radical prostatectomy. Current Opinion in Urology, 2010, 20, 204-210.	0.9	15
215	Impact of Pathogenic Germline DNA Damage Repair alterations on Response to Intense Neoadjuvant Androgen Deprivation Therapy in High-risk Localized Prostate Cancer. European Urology, 2021, 80, 295-303.	0.9	15
216	Validation of a multi-ancestry polygenic risk score and age-specific risks of prostate cancer: A meta-analysis within diverse populations. ELife, 0, 11, .	2.8	15

#	Article	IF	Citations
217	Xq27-28 deletions in prostate carcinoma. Genes Chromosomes and Cancer, 2003, 37, 381-388.	1.5	14
218	Efficacy of robotâ€assisted radical cystectomy (<scp>RARC</scp>) in advanced bladder cancer: results from the <scp>I</scp>nternational <scp>R</scp>adical <scp>C</scp>ystectomy <scp>C</scp>onsortium (<scp>IRCC</scp>). BJU International, 2014, 114, 98-103.	1.3	14
219	Chronic kidney disease and perioperative outcomes in urological oncological surgery. International Journal of Urology, 2014, 21, 1245-1252.	0.5	14
220	The effect of sample size on polygenic hazard models for prostate cancer. European Journal of Human Genetics, 2020, 28, 1467-1475.	1.4	14
221	A Selective Androgen Receptor Modulator (OPK-88004) in Prostate Cancer Survivors: A Randomized Trial. Journal of Clinical Endocrinology and Metabolism, 2021, 106, 2171-2186.	1.8	14
222	Mobile Health App for Prostate Cancer Patients on Androgen Deprivation Therapy: Qualitative Usability Study. JMIR MHealth and UHealth, 2020, 8, e20224.	1.8	14
223	Prostate cancer risk stratification improvement across multiple ancestries with new polygenic hazard score. Prostate Cancer and Prostatic Diseases, 2022, 25, 755-761.	2.0	14
224	RB1 loss overrides PARP inhibitor sensitivity driven by RNASEH2B loss in prostate cancer. Science Advances, 2022, 8, eabl9794.	4.7	14
225	Risk factors and reasons for reoperation after radical cystectomy. Urologic Oncology: Seminars and Original Investigations, 2020, 38, 269-277.	0.8	13
226	miR-218 Expressed in Endothelial Progenitor Cells Contributes to the Development and Repair of the Kidney Microvasculature. American Journal of Pathology, 2020, 190, 642-659.	1.9	13
227	Trends in nephron-sparing surgery for renal neoplasia. Urology, 2006, 68, 732-736.	0.5	12
228	Genetic variants in cell cycle control pathway confer susceptibility to aggressive prostate carcinoma. Prostate, 2016, 76, 479-490.	1.2	12
229	Characterizing trends in treatment modalities for localized muscle-invasive bladder cancer in the pre-immunotherapy era. World Journal of Urology, 2018, 36, 1767-1774.	1.2	12
230	Differences in survival and impact of adjuvant chemotherapy in patients with variant histology of tumors of the renal pelvis. World Journal of Urology, 2020, 38, 2227-2236.	1.2	12
231	Genomic Features of Muscle-invasive Bladder Cancer Arising After Prostate Radiotherapy. European Urology, 2022, 81, 466-473.	0.9	12
232	An interdisciplinary approach to treating prostate cancer. Urology, 2005, 65, 13-18.	0.5	11
233	Preventable mortality after common urological surgery: failing to rescue?. BJU International, 2015, 115, 666-674.	1.3	11
234	SNP interaction pattern identifier (SIPI): an intensive search for SNPâ€“SNP interaction patterns. Bioinformatics, 2017, 33, 822-833.	1.8	11

#	Article	IF	Citations
235	Use of Preventive Health Services Among Cancer Survivors in the U.S.. American Journal of Preventive Medicine, 2018, 55, 830-838.	1.6	11
236	Variation in Positive Surgical Margin Status After Radical Prostatectomy for pT2 Prostate Cancer. Clinical Genitourinary Cancer, 2019, 17, e1060-e1068.	0.9	11
237	Contemporary Survival Rates for Muscle-Invasive Bladder Cancer Treated With Definitive or Non-Definitive Therapy. Clinical Genitourinary Cancer, 2019, 17, e488-e493.	0.9	11
238	Effect of Medicaid Expansion on Receipt of Definitive Treatment and Time to Treatment Initiation by Racial and Ethnic Minorities and at Minority-Serving Hospitals: A Patient-Level and Facility-Level Analysis of Breast, Colon, Lung, and Prostate Cancer. JCO Oncology Practice, 2021, 17, e654-e665.	1.4	11
239	Adverse pathologic characteristics in the small renal mass: implications for active surveillance. Canadian Journal of Urology, 2017, 24, 8759-8764.	0.0	11
240	The Effect of Resident Involvement on Surgical Outcomes for Common Urologic Procedures: A Case Study of Uni- and Bilateral Hydrocele Repair. Urology, 2016, 94, 70-76.	0.5	10
241	The Use of Prostate Specific Antigen Screening in Purchased versus Direct Care Settings: Data from the TRICAREÂ® Military Database. Journal of Urology, 2017, 198, 1295-1300.	0.2	10
242	The impact of age at the time of radiotherapy for localized prostate cancer on the development of second primary malignancies. Urologic Oncology: Seminars and Original Investigations, 2018, 36, 500.e11-500.e19.	0.8	10
243	The impact of smoking on radical cystectomy complications increases in elderly patients. Cancer, 2021, 127, 1387-1394.	2.0	10
244	Systematic Review of Time to Definitive Treatment for Intermediate Risk and High Risk Prostate Cancer: Are Delays Associated with Worse Outcomes?. Journal of Urology, 2021, 205, 1263-1274.	0.2	10
245	The use and abuse of data: Nomograms and talking to patients about clinical medicine. Urologic Oncology: Seminars and Original Investigations, 2007, 25, 333-337.	0.8	9
246	New Trends in the Surgical Management of Invasive Bladder Cancer. Hematology/Oncology Clinics of North America, 2015, 29, 253-269.	0.9	9
247	Contemporary nationwide patterns of self-reported prostate-specific antigen screening in US veterans. Urologic Oncology: Seminars and Original Investigations, 2015, 33, 503.e7-503.e15.	0.8	9
248	Adverse Histopathologic Characteristics in Small Clear Cell Renal Cell Carcinomas Have Negative Impact on Prognosis. American Journal of Surgical Pathology, 2019, 43, 1413-1420.	2.1	9
249	The Translational and Regulatory Development of an Implantable Microdevice for Multiple Drug Sensitivity Measurements in Cancer Patients. IEEE Transactions on Biomedical Engineering, 2022, 69, 412-421.	2.5	9
250	Performance of African-ancestry-specific polygenic hazard score varies according to local ancestry in 8q24. Prostate Cancer and Prostatic Diseases, 2022, 25, 229-237.	2.0	9
251	Optimal timing of sipuleucel-T treatment in metastatic castration-resistant prostate cancer. Canadian Journal of Urology, 2015, 22, 8048-55.	0.0	9
252	Constitutive expression of high levels of prostate-specific antigen in the absence of prostate carcinoma. Urology, 1996, 48, 741-746.	0.5	8

#	Article	IF	Citations
253	An evaluation of the â€˜weekend effectâ€™ in patients admitted with metastatic prostate cancer. BJU International, 2015, 116, 911-919.	1.3	8
254	The Contemporary Incidence and Sequelae of Rhabdomyolysis Following Extirpative Renal Surgery: A Population Based Analysis. Journal of Urology, 2016, 195, 399-405.	0.2	8
255	Recommended Cancer Screening in Accountable Care Organizations: Trends in Colonoscopy and Mammography in the Medicare Shared Savings Program. Journal of Oncology Practice, 2019, 15, e547-e559.	2.5	8
256	Prostate cancer in the medicare shared savings program: are Accountable Care Organizations associated with reduced expenditures for men with prostate cancer?. Prostate Cancer and Prostatic Diseases, 2019, 22, 593-599.	2.0	8
257	Implementation of a Perioperative Venous Thromboembolism Prophylaxis Program for Patients Undergoing Radical Cystectomy on an Enhanced Recovery After Surgery Protocol. European Urology Focus, 2020, 6, 74-80.	1.6	8
258	Domain adaptation for segmentation of critical structures for prostate cancer therapy. Scientific Reports, 2021, 11, 11480.	1.6	8
259	Randomized phase II trial evaluating the optimal sequencing of sipuleucel-T and androgen-deprivation therapy (ADT) in patients (pts) with biochemically recurrent prostate cancer (BRPC).. Journal of Clinical Oncology, 2013, 31, 34-34.	0.8	8
260	PROTEUS: A randomized, double-blind, placebo (PBO)-controlled, phase III trial of apalutamide (APA) plus androgen deprivation therapy (ADT) versus PBO plus ADT prior to radical prostatectomy (RP) in patients with localized high-risk or locally advanced prostate cancer (PC).. Journal of Clinical Oncology, 2020, 38, TPS383-TPS383.	0.8	8
261	Predicting Risk of Bladder Cancer Using Clinical and Demographic Information from Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial Participants. Cancer Epidemiology Biomarkers and Prevention, 2013, 22, 2241-2249.	1.1	7
262	Calcium intake, polymorphisms of the calcium-sensing receptor, and recurrent/aggressive prostate cancer. Cancer Causes and Control, 2015, 26, 1751-1759.	0.8	7
263	Complications Following Common Inpatient Urological Procedures: Temporal Trend Analysis from 2000 to 2010. European Urology Focus, 2016, 2, 3-9.	1.6	7
264	Contemporary trends in the utilisation of radical prostatectomy. BJU International, 2018, 122, 726-728.	1.3	7
265	Quantifying the Overall Survival Benefit With Early Radical Cystectomy for Patients With Histologically Confirmed T1 Nonâ€“muscle-invasive Bladder Cancer. Clinical Genitourinary Cancer, 2020, 18, e651-e659.	0.9	7
266	Results of a phase II trial of intense androgen deprivation therapy prior to radical prostatectomy (RP) in men with high-risk localized prostate cancer (PC).. Journal of Clinical Oncology, 2020, 38, 5503-5503.	0.8	7
267	Targeting the Androgen Receptorâ€”Theory and Practice. Urology, 2011, 78, S482-S484.	0.5	6
268	Exploring exposure to Agent Orange and increased mortality due to bladder cancer. Urologic Oncology: Seminars and Original Investigations, 2017, 35, 627-632.	0.8	6
269	Approach to the Patient with High-Risk Prostate Cancer. Urologic Clinics of North America, 2017, 44, 635-645.	0.8	6
270	Multilevel Analysis of Readmissions After Radical Cystectomy for Bladder Cancer in the USA: Does the Hospital Make a Difference?. European Urology Oncology, 2019, 2, 349-354.	2.6	6

#	Article	IF	Citations
271	Minimally invasive cancer surgery is associated with a lower risk of venous thromboembolic events. Journal of Surgical Oncology, 2020, 121, 578-583.	0.8	6
272	Delayed nephrectomy has comparable long-term overall survival to immediate nephrectomy for cT1a renal cell carcinoma: A population-based analysis. Urologic Oncology: Seminars and Original Investigations, 2020, 38, 74.e13-74.e20.	0.8	6
273	Alvimopan Is Associated With a Reduction in Length of Stay and Hospital Costs for Patients Undergoing Radical Cystectomy. Urology, 2020, 140, 115-121.	0.5	6
274	PROTEUS: A randomized, double-blind, placebo (PBO)-controlled, phase 3 trial of apalutamide (APA) plus androgen deprivation therapy (ADT) versus PBO plus ADT prior to radical prostatectomy (RP) in patients with localized high-risk or locally advanced prostate cancer (PC).. Journal of Clinical Oncology, 2019, 37, TPS5100-TPS5100.	0.8	6
275	Indications and Practice With Androgen Deprivation Therapy. Urology, 2011, 78, S478-S481.	0.5	5
276	Pathologic correlation of transperineal in-bore 3-Tesla magnetic resonance imaging-guided prostate biopsy samples with radical prostatectomy specimen. Abdominal Radiology, 2017, 42, 2154-2159.	1.0	5
277	Assessing robot-assisted laparoscopic prostatectomy. Lancet, The, 2017, 389, 799.	6.3	5
278	The current landscape of low-value care in men diagnosed with prostate cancer: what is the role of individual hospitals?. Urologic Oncology: Seminars and Original Investigations, 2019, 37, 575.e9-575.e18.	0.8	5
279	Trends in Adherence to Thromboprophylaxis Guideline in Patients Undergoing Radical Cystectomy. Urology, 2020, 135, 44-49.	0.5	5
280	KLK3 SNPâ€“SNP interactions for prediction of prostate cancer aggressiveness. Scientific Reports, 2021, 11, 9264.	1.6	5
281	A randomized phase II study evaluating the optimal sequencing of sipuleucel-T and androgen deprivation therapy (ADT) in biochemically recurrent prostate cancer (BRPC): Immune results.. Journal of Clinical Oncology, 2013, 31, 5016-5016.	0.8	5
282	DNA Repair Pathways and Their Association With Lethal Prostate Cancer in African American and European American Men. JNCI Cancer Spectrum, 2022, 6, pkab097.	1.4	5
283	Local treatment of high risk prostate cancer: Role of surgery and radiation therapy. Cancer, 2014, 120, 1608-1610.	2.0	4
284	Risk of Small Bowel Obstruction After Robot-Assisted vs Open Radical Prostatectomy. Journal of Endourology, 2016, 30, 1291-1295.	1.1	4
285	Resident Involvement in Radical Inguinal Orchiectomy for Testicular Cancer Does Not Adversely Impact Perioperative Outcomes - A Retrospective Study. Urologia Internationalis, 2017, 98, 472-477.	0.6	4
286	Health care spending in prostate cancer: An assessment of characteristics and health care utilization of high resource-patients. Urologic Oncology: Seminars and Original Investigations, 2021, 39, 130.e17-130.e24.	0.8	4
287	Is Medicaid expansion associated with increases in palliative treatments for metastatic cancer?. Journal of Comparative Effectiveness Research, 2021, 10, 733-741.	0.6	4
288	Impact of high-intensity local treatment on overall survival in stage IV upper tract urothelial carcinoma. Urologic Oncology: Seminars and Original Investigations, 2021, 39, 436.e1-436.e10.	0.8	4

#	Article	IF	Citations
289	Recovery from minimally invasive vs. open surgery in kidney cancer patients: Opioid use and workplace absenteeism. Investigative and Clinical Urology, 2021, 62, 56.	1.0	4
290	Facility Level Variation in Rates of Definitive Therapy for Low Risk Prostate Cancer in Men with Limited Life Expectancy: An Opportunity for Value Based Care Redesign. Journal of Urology, 2019, 201, 728-734.	0.2	4
291	Metabolic syndrome and its pharmacologic treatment are associated with the time to castration-resistant prostate cancer. Prostate Cancer and Prostatic Diseases, 2022, 25, 320-326.	2.0	4
292	Parenchymal imaging adds diagnostic utility in evaluating haematuria. BJU International, 2005, 95, 64-67.	1.3	3
293	TMPRSS2:ERG gene fusion associated with lethal prostate cancer in a watchful waiting cohort. Urologic Oncology: Seminars and Original Investigations, 2007, 25, 448-449.	0.8	3
294	Caution with Use of the EPIC-50 Urinary Bother Scale: How Voiding Dysfunction Modifies its Performance. Journal of Urology, 2017, 198, 1397-1403.	0.2	3
295	The association of weight change in young adulthood and smoking status with risk of prostate cancer recurrence. International Journal of Cancer, 2018, 142, 2011-2018.	2.3	3
296	AA9int: SNP interaction pattern search using non-hierarchical additive model set. Bioinformatics, 2018, 34, 4141-4150.	1.8	3
297	Facility-Level Variation in Pelvic Lymphadenectomy During Radical Prostatectomy and Effect on Overall Survival in Men with High-Risk Prostate Cancer. Annals of Surgical Oncology, 2020, 27, 1929-1936.	0.7	3
298	Delay in surgery for cT1b-2 kidney cancer beyond 90 days is associated with poorer survival: implications for prioritization during the COVID-19 pandemic. Minerva Urology and Nephrology, 2021, 73, 404-406.	1.3	3
299	Cyclophosphamide-associated bladder cancers and considerations for survivorship care: A systematic review. Urologic Oncology: Seminars and Original Investigations, 2021, 39, 678-685.	0.8	3
300	Impact of Accountable Care Organizations on Prostate Cancer Screening and Biopsies in the United States. Urology Practice, 2019, 6, 159-164.	0.2	3
301	Immune responses and clinical outcomes in STAND, a randomized phase 2 study evaluating optimal sequencing of sipuleucel-T (sip-T) and androgen deprivation therapy (ADT) in biochemically-recurrent prostate cancer (BRPC) after local therapy failure.. Journal of Clinical Oncology, 2015, 33, 5030-5030.	0.8	3
302	Antigen-specific immune responses through 24 months in the STAND trial: A randomized phase 2 study evaluating optimal sequencing of sipuleucel-T (sip-T) and androgen deprivation therapy (ADT) in biochemically-recurrent prostate cancer (BRPC).. Journal of Clinical Oncology, 2015, 33, 171-171.	0.8	3
303	PROTEUS: A randomized, double-blind, placebo (PBO)-controlled, phase 3 trial of apalutamide (APA) plus androgen deprivation therapy (ADT) versus PBO plus ADT prior to radical prostatectomy (RP) in patients (pts) with localized or locally advanced high-risk prostate cancer (PC).. Journal of Clinical Oncology, 2022, 40, TPS285-TPS285.	0.8	3
304	5-alpha reductase inhibitors and prostate cancer mortality among men with regular access to screening and health care. Cancer Epidemiology Biomarkers and Prevention, 2022, , .	1.1	3
305	Re: Enzalutamide in Metastatic Prostate Cancer Before Chemotherapy. European Urology, 2015, 67, 174.	0.9	2
306	30-Day Adverse Events Following Cystectomy for Bladder Cancer Versus Benign Bladder Conditions. Urology Practice, 2017, 4, 388-394.	0.2	2

#	Article	IF	Citations
307	Contemporary perceptions of human papillomavirus and penile cancer: Perspectives from a national survey. Canadian Urological Association Journal, 2018, 13, 32-37.	0.3	2
308	Association of surgical approach and prolonged opioid prescriptions in patients undergoing major pelvic cancer procedures. BMC Surgery, 2020, 20, 235.	0.6	2
309	Workplace absenteeism amongst patients undergoing open vs. robotic radical prostatectomy, hysterectomy, and partial colectomy. Surgical Endoscopy and Other Interventional Techniques, 2021, 35, 1644-1650.	1.3	2
310	Videos of Sipuleucel-T Programmed T Cells Lysing Cells That Express Prostate Cancer Target Antigens. Journal of the National Cancer Institute, 2022, 114, 310-313.	3.0	2
311	Abstract 822: Can the genetic risk of prostate cancer be attenuated by a healthy lifestyle. , 2021, , .		2
312	Association between Operative Time and Short-Term Radical Cystectomy Complications. Urologia Internationalis, 2023, 107, 273-279.	0.6	2
313	Genome-wide association study of prostate cancer identifies a second risk locus at 8q24. Urologic Oncology: Seminars and Original Investigations, 2007, 25, 447-448.	0.8	1
314	Re: Prostate Cancer-Specific Mortality After Radical Prostatectomy for Patients Treated in the Prostate-Specific Antigen Era. European Urology, 2009, 56, 1089-1090.	0.9	1
315	Rebuttal to Dr. Wallner. Brachytherapy, 2010, 9, 200-201.	0.2	1
316	Counterpoint: Prostate carcinoma treatment for the young patientâ€"The case for radical prostatectomy. Brachytherapy, 2010, 9, 195-198.	0.2	1
317	Re: Active Surveillance Compared with Initial Treatment for Men with Low-Risk Prostate Cancer: A Decision Analysis. European Urology, 2011, 59, 883-884.	0.9	1
318	A Nationwide Survey of Prostate Specific Antigen Based Screening and Counseling for Prostate Cancer. Urology Practice, 2017, 4, 210-217.	0.2	1
319	Factors Influencing Prostate Specific Antigen Testing in the United States. Urology Practice, 2018, 5, 438-443.	0.2	1
320	Delayed blood transfusion is associated with mortality following radical cystectomy. Scandinavian Journal of Urology, 2020, 54, 290-296.	0.6	1
321	One-year urinary and sexual outcome trajectories among prostate cancer patients treated by radical prostatectomy: a prospective study. BMC Urology, 2021, 21, 81.	0.6	1
322	The impact of histological variants on bladder cancer survival: A population-based analysis.. Journal of Clinical Oncology, 2016, 34, 458-458.	0.8	1
323	Antigen spread (AgS) after sipuleucel-T (sip-T): A cross-trial comparison of 4 sip-T clinical trials of patients (pts) with prostate cancer (PC).. Journal of Clinical Oncology, 2017, 35, 143-143.	0.8	1
324	Impact of variant histology on disease-specific mortality and survival in patients with non-muscle invasive bladder cancer (NMIBC): A population-based analysis.. Journal of Clinical Oncology, 2017, 35, 332-332.	0.8	1

#	Article	IF	Citations
325	Sipuleucel-T (sip-T)â€“induced proliferative CD8+ T-cell responses to immunizing and secondary antigens.. Journal of Clinical Oncology, 2016, 34, 165-165.	0.8	1
326	Adverse effects of ADT on cognitive function and dementia for men with prostate cancer: A meta-analysis and systematic review.. Journal of Clinical Oncology, 2017, 35, 150-150.	0.8	1
327	Temporal changes in the screening, diagnosis and surgical treatment of genitourinary (GU) malignancies during the COVID-19 pandemic.. Journal of Clinical Oncology, 2022, 40, 281-281.	0.8	1
328	Hormone Treatment of Prostate Cancer:. Urologic Clinics of North America, 2022, 49, 309-321.	0.8	1
329	Preoperative anemia is associated with increased radical cystectomy complications. Urologic Oncology: Seminars and Original Investigations, 2022, 40, 382.e7-382.e13.	0.8	1
330	Prostatic Diseases. Journal of Urology, 2000, 163, 2054-2054.	0.2	0
331	Single nucleotide polymorphisms: Early diagnosis and risk assessment in genitourinary malignancy. Urologic Oncology: Seminars and Original Investigations, 2006, 24, 224-230.	0.8	0
332	Integrative molecular concept modeling of prostate cancer progression. Urologic Oncology: Seminars and Original Investigations, 2007, 25, 449-450.	0.8	0
333	An infectious retrovirus susceptible to an IFN antiviral pathway from human prostate tumors. Urologic Oncology: Seminars and Original Investigations, 2007, 25, 450.	0.8	0
334	Intravesical BCG therapy for non-muscle-invasive bladder cancer: Effect of concurrent statin therapy. Journal of the American College of Surgeons, 2008, 207, S110-S111.	0.2	0
335	Commentary on Transcriptome sequencing to detect gene fusions in cancer. Urologic Oncology: Seminars and Original Investigations, 2009, 27, 461-462.	0.8	0
336	Commentary on Cumulative association of five genetic variants with prostate cancer. Urologic Oncology: Seminars and Original Investigations, 2009, 27, 462-463.	0.8	0
337	Commentary on Germline SDHB mutations and familial renal cell carcinoma. Urologic Oncology: Seminars and Original Investigations, 2009, 27, 463-464.	0.8	0
338	Reply from Authors re: Urs E. Studer, Laurence Collette. Robot-Assisted Cystectomy: Does It Meet Expectations? Eur Urol 2010;58:203â€“4. European Urology, 2010, 58, 204-206.	0.9	0
339	Editorial for â€œprediction of significant prostate cancer diagnosed 20 to 30 years later with a single measure of prostateâ€specific antigen at or before age 50â€. Cancer, 2011, 117, 1110-1112.	2.0	0
340	Preface. Urologic Clinics of North America, 2012, 39, xv.	0.8	0
341	Reply from Authors re: Manfred P. Wirth, Johannes Huber. What Really Matters Is Rarely Measured: Outcome of Routine Care and Patient-reported Outcomes. Eur Urol 2013;64:58â€“9. European Urology, 2013, 64, 60-61.	0.9	0
342	Editorial Comment. Journal of Urology, 2013, 189, 853-853.	0.2	0

#	Article	IF	Citations
343	Response to Letter to the Editor. Journal of Urology, 2013, , .	0.2	0
344	Reply to Michael Froehner's Letter to the Editor re: Kenneth G. Nepple, Andrew J. Stephenson, Dorina Kallogjeri, et al. Mortality After Prostate Cancer Treatment with Radical Prostatectomy, External-Beam Radiation Therapy, or Brachytherapy in Men Without Comorbidity. Eur Urol 2013;64:372â€“8. European Urology, 2014, 65, e42.	0.9	0
345	Intermediate Risk Prostate Cancer and Active Surveillance: Maximize Utilization while Minimizing Failure. Journal of Urology, 2017, 198, 493-495.	0.2	0
346	Editorial Comment. Journal of Urology, 2018, 199, 712-712.	0.2	0
347	The bladder cancer conundrum: how do we treat the right tumour with the right treatment, at the right time?. BJU International, 2019, 123, 748-749.	1.3	0
348	Re: Association of Robotic-Assisted vs Laparoscopic Radical Nephrectomy with Perioperative Outcomes and Health Care Costs, 2003 to 2015. European Urology, 2019, 75, 696-697.	0.9	0
349	EDITORIAL COMMENT. Urology, 2020, 139, 42-43.	0.5	0
350	AUTHOR REPLY. Urology, 2020, 140, 121.	0.5	0
351	Reply by Authors. Journal of Urology, 2021, 205, 1274-1274.	0.2	0
352	Adverse Histopathologic Characteristics in Small Papillary Renal Cell Carcinomas Have Minimal Impact on Prognosis. American Journal of Clinical Pathology, 2021, 156, 550-558.	0.4	0
353	Prospective evaluation of testosterone (T) recovery and PSA relapse following 18 months of androgen deprivation (ADT) after prostatectomy (RP): Results from the TAX-3501 trial.. Journal of Clinical Oncology, 2013, 31, 5023-5023.	0.8	0
354	Sipuleucel-T (sip-T)â€“induced lytic CD8+ T cell responses to target antigens in men with hormone-sensitive and castration-resistant prostate cancer (CRPC).. Journal of Clinical Oncology, 2016, 34, e23116-e23116.	0.8	0
355	Effect of a genomic classifier on adjuvant treatment decision-making among patients with high-risk pathology at radical prostatectomy: Results from the multicenter prospective PRO-IMPACT study.. Journal of Clinical Oncology, 2016, 34, 5053-5053.	0.8	0
356	Effect of a genomic classifier on treatment decision-making among patients with biochemical recurrence after radical prostatectomy: Results from the multicenter prospective PRO-IMPACT study.. Journal of Clinical Oncology, 2016, 34, e16558-e16558.	0.8	0
357	Effect of decipher test on adjuvant treatment decision-making among men with high-risk pathology at radical prostatectomy: Results from a multicenter prospective PRO-IMPACT study.. Journal of Clinical Oncology, 2017, 35, 24-24.	0.8	0
358	Sipuleucel-T (sip-T) induced lytic CD8+ T cell responses to target antigens in men with hormone-sensitive and castration-resistant prostate cancer (CRPC).. Journal of Clinical Oncology, 2017, 35, 162-162.	0.8	0
359	Cytokine profile of sipuleucel-T (sip-T) in differentiating reactivation of latent immunity from de novo immune responses.. Journal of Clinical Oncology, 2017, 35, 163-163.	0.8	0
360	Sipuleucel-T (sip-T) to induce cytolytic T lymphocyte (CTL) activity against target antigens in men with hormone-sensitive and castration-resistant prostate cancer (CRPC).. Journal of Clinical Oncology, 2017, 35, 5046-5046.	0.8	0

#	Article	IF	Citations
361	5-alpha reductase inhibitors (5-ARI) and prostate cancer mortality among men with regular access to screening and health care.. Journal of Clinical Oncology, 2020, 38, 39-39.	0.8	0
362	Impact of MRI on outcomes in active surveillance (AS) for localized prostate cancer in a hospital registry.. Journal of Clinical Oncology, 2020, 38, 280-280.	0.8	0
363	Perioperative Acid Suppression in Bladder Cancer Patients Undergoing Radical Cystectomy: A Population-Based Analysis. Journal of the American College of Surgeons, 2021, 233, S309.	0.2	0
364	â€˜Case of the Monthâ€™ from Brigham and Womenâ€™s Hospital, Boston, MA, USA: a 70â€yearâ€old man with lung cysts and bilateral renal masses. BJU International, 2020, 126, 428-432.	1.3	0